ProCE Banner Activity

Interactive Tool With Expert Guidance for the Treatment of CLL: An International Perspective

Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with CLL with those of 5 renowned international experts.

Released: March 25, 2025

Expiration: September 24, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Toby A. Eyre, MBChB, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Autolus, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, Incyte, Janssen, Kite, Loxo Oncology, Roche; researcher: AstraZeneca, BeiGene, Gilead.

Arnon Kater, MD, MPH: advisor/speaker (paid to institution): AbbVie, Bristol Myers Squibb, Janssen, LAVA, Roche/Genentech; researcher (paid to institution): AbbVie, Bristol Myers Squibb, Janssen, Lilly, Roche/Genentech; patent (paid to institution): Janssen, LAVA.

Vincent Ribrag, MD: consultant/advisor/speaker: AstraZeneca, Lilly; researcher: Astex, GSK; employee: Pegascy.

Stephan Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Lilly, Novartis, Sunesis.

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Johnson & Johnson.